Enveric Biosciences Plans About 35 Percent Reduction In Full-time Personnel
(RTTNews) - Biotechnology company Enveric Biosciences, Inc. (ENVB) announced Monday a cost reduction plan resulting in approximately 40% to 55% decrease in expenses and extension of financial runway into the first quarter of 2024.
The operational streamlining entailed an approximately 35 percent reduction in full-time personnel, the cancelation of 7 consulting contracts focused on the cannabinoid programs and a transition from third-party service providers supporting R&D efforts to internal science teams performing this work.
The company also announced the termination of proposed spin-off of cannabinoid clinical development pipeline to a publicly traded company, Akos Biosciences, Inc. Enveric is now engaging with strategic advisors to identify and pursue alternative value-creating opportunities for cannabinoid assets.
Aries Science Inks Licensing Deal For Enveric Biosciences' Radiation Dermatitis Topical Product
China Bourse: Resistance Expected At 3,700 Points
Lower Open Predicted For Taiwan Stock Market
Little Movement Expected For Singapore Stock Market
New Zealand Services Index Improves To 48.9 - BusinessNZ
Malaysia Bourse Likely To Remain Rangebound On Monday
Japan Shares Due For Profit Taking On Monday
